The number of hospital discharges for malignant neoplasm of the prostate in France is forecasted to increase from 34.97 thousand in 2024 to 35.38 thousand by 2028. This reflects a gradual year-on-year growth rate of approximately 0.28%. Compared to 2023, where discharges were slightly lower, this suggests a steady upward trend. Over a five-year period from 2024 to 2028, the compound annual growth rate (CAGR) is expected to be modest, indicating overall stability in discharge rates for this condition.
Future trends to monitor include advancements in early detection and treatment efficiencies, which may impact hospitalization needs. Additionally, changes in healthcare policies or patient demographics could alter projected trends.
